Seeking Alpha

Leerink Swann weighs in on Dendreon's (DNDN -21%) mixed Q1 results yesterday, downgrading the...

Leerink Swann weighs in on Dendreon's (DNDN -21%) mixed Q1 results yesterday, downgrading the shares to Market Perform on the back of the report. The firm cites less-than-expected growth of Provenge and concerns over growing competition.
Comments (1)
  • Gary Jakacky
    , contributor
    Comments (2414) | Send Message
     
    Hahahahahahahahah

     

    Pro-venge: an overpriced ineffective drug.

     

    Neu-venge: an overpriced ineffective sequel.

     

    RE-VENGE: the joy of watchiing DNDN collapse...again!
    8 May 2012, 11:25 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|